RRx-001 protects against cisplatin-induced toxicities
- 231 Downloads
RRx-001, a minimally toxic tumor-associated macrophage and neutrophil-repolarizing agent, is under investigation in Phase II clinical trials as a sensitizer/resensitizer to cisplatin and carboplatin. On the basis of anecdotal clinical observations of improved platinum tolerability following a priming period with RRx-001 as well as preclinical studies that have previously demonstrated radioprotection of intestinal stem cells and cardioprotection from doxorubicin, the in vivo cytoprotective potential of RRx-001 pretreatment against cisplatin-induced bone marrow suppression and renal toxicity was investigated.
BALB/c mice were divided into three groups: (1) no treatment, (2) vehicle and cisplatin only, and (3) RRx-001 and cisplatin. RRx-001 treatment (5 mg/kg every other day for 3 days) was initiated 3 days prior to cisplatin administration. Blood was collected from the femoral vein at different intervals to measure total hemoglobin and leukocyte counts as well as renal functional markers (serum urea, creatinine and creatinine clearance). Metaphase spreads were prepared from whole bone marrow cells as markers of clastogenicity.
RRx-001 pretreatment significantly decreased (P < 0.05) the blood urea nitrogen and creatinine levels. A statistically significant (P < 0.05) reduction in the mean total chromosome aberration frequency per metaphase in the RRx-001 and cisplatin group compared to the cisplatin-only group was observed.
This study is the first to demonstrate that RRx-001 has nephro-, geno- and myeloprotective effects in vivo. Importantly, RRx-001 did not protect sarcoma-180 solid tumor xenografts against cisplatin-induced cytotoxicity. These results potentially support the use of RRx-001 as a chemoprotector against cisplatin-induced toxicities.
KeywordsCisplatin Toxicity sparing Chemoprotection RRx-001 Myeloprotection
This study was funded by EpicentRx.
P Cabrales designed the experiments, acquired and analyzed data, and participated in the drafting of the manuscript. All authors analyzed data and participated in the drafting of the manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
EpicentRx Inc funds research of molecule RRx-001. B. Oronsky is an employee of EpicentRx. P. Cabrales and the other authors have no conflicts of interest to declare.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J (2015) Flushing out carcinoid syndrome: beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor. Case Rep Oncol 8:461–465CrossRefPubMedPubMedCentralGoogle Scholar
- Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B (2016a) Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget 7:40781–40791. doi: 10.18632/oncotarget.8205 CrossRefPubMedPubMedCentralGoogle Scholar
- Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N et al (2016b) RRx-001 in refractory small-cell lung carcinoma: a case report of a partial response after a third reintroduction of platinum doublets. Case Rep Oncol 9:171–176CrossRefPubMedPubMedCentralGoogle Scholar
- Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR et al (2016c) Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001. Case Rep Oncol 9:164–170CrossRefPubMedPubMedCentralGoogle Scholar
- Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA et al (2016b) Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: a TITE-CRM phase I/II clinical trial. Transl Oncol 9:108–113CrossRefPubMedPubMedCentralGoogle Scholar
- National Research Council of the National Academies (2011) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington, DCGoogle Scholar
- Oronsky B, Ao-ieong ES, Yalcin O, Scicinski J, Caroen S, Reid TR, Carter CA, Oronsky A, Cabrales P (2017) Cardioprotective effect of the clinical anticancer agent, RRx-001, in doxorubicin-induced acute cardiotoxicity in mice Google Scholar